



12th August, 2026

To, Department of Corporate Services BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. Ref.: Scrip Code No. : 540701 (Equity) : 975834, 976560, 977467 and 977859 (Debt)	To, The Manager, Listing Department, National Stock Exchange of India Ltd. “Exchange Plaza”, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. Ref. : (i) Symbol – DCAL (ii) Series – EQ
--	--

SUB: REVISED INTIMATION OF CONFERENCE CALL

Dear Sir,

With reference to our earlier intimation dated 12th August, 2026 regarding intimation of conference call arranged with Investors on Monday, 17th August, 2026 at 17:00 hrs. (IST) to discuss the financial result and performance of the Company for the first quarter ended on 30th June, 2026, we wish to inform you that the registration link posted was not verified.

We hereby attached the revised Conference Call details with correct registration link for accessing the conference call.

Kindly take the same on your record.

Thanking You,
Yours faithfully,

For, Dishman Carbogen Amcis Limited

Shrima Dave
Company Secretary

Encl.: As Above



Dishman Carbogen Amcis Limited to announce its Q1FY27 results on 14 Aug 2026. The management of the company to host

Q1FY27 Earnings Conference Call on

17 Aug 2026 at 17:00hrs - 18:00hrs, IST



Primary Numbers

086 3416 8589 /
086 4536 7374

International Toll-Free Numbers

USA - 18773870849 | Singapore - 8001011941
UK - 08000163439 | Hong Kong - 800903171

International Participation PIN No.: 8630176#

Pre-Registration Facility

(Express Join with DiamondPass™ to avoid long queue and save time)

[Click Here](#) to pre-register for the call and dial in directly without waiting for the operator.

Management Represented by:

Mr. Harshil Dalal

Global CFO

Mr. Stephan Fritschi

Chief Executive Officer, Carbogen Amcis Entities

About Dishman Carbogen Amcis Limited

Established in 1983, Dishman Carbogen Amcis Limited is a fully integrated CDMO (Contract Development and Manufacturing Organisation) company with strong capabilities right from process research & development to late-stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical companies. The company has global presence with development and manufacturing sites in Switzerland, UK, France, Netherlands, India, and China.

The company provides end-to-end integrated high-value niche CDMO offering and has comprehensive product offerings which include APIs, High Potent APIs, Intermediates, Phase Transfer Catalysts, Vitamin D Analogues, Cholesterol, Lanolin-related products, Antiseptic and Disinfectant formulations.

For details, please visit www.imdcal.com.

For details please contact:

Harshil Dalal

Global CFO

P: +91 22 22867597

E: harshil.dalal@dishmangroup.com

Krishna Patel

Ernst & Young LLP

P: +91 9998236402

E: krishna.patel2@in.ey.com